These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 27048228)

  • 1. Bortezomib may stabilize pediatric renal transplant recipients with antibody-mediated rejection.
    Pearl MH; Nayak AB; Ettenger RB; Puliyanda D; Palma Diaz MF; Zhang Q; Reed EF; Tsai EW
    Pediatr Nephrol; 2016 Aug; 31(8):1341-8. PubMed ID: 27048228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection.
    Walsh RC; Everly JJ; Brailey P; Rike AH; Arend LJ; Mogilishetty G; Govil A; Roy-Chaudhury P; Alloway RR; Woodle ES
    Transplantation; 2010 Feb; 89(3):277-84. PubMed ID: 20145517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
    Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
    Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and pathological analyses of transplant glomerulopathy cases.
    Shimizu T; Ishida H; Toki D; Nozaki T; Omoto K; Tanabe K; Honda K; Koike J
    Nephrology (Carlton); 2014 Jun; 19 Suppl 3():21-6. PubMed ID: 24842817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bortezomib for refractory acute antibody-mediated rejection in kidney transplant recipients: A single-centre case series.
    De Sousa-Amorim E; Revuelta I; Diekmann F; Cofan F; Lozano M; Cid J; Palou E; Sole M; Campistol JM; Oppenheimer F
    Nephrology (Carlton); 2016 Aug; 21(8):700-4. PubMed ID: 26492594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impacts of donor-specific anti-HLA antibodies and antibody-mediated rejection on outcomes after intestinal transplantation in children.
    Petit LM; Rabant M; Canioni D; Suberbielle-Boissel C; Goulet O; Chardot C; Lacaille F
    Pediatr Transplant; 2017 Mar; 21(2):. PubMed ID: 28084679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Donor-specific antibodies against HLA, MICA, and GSTT1 in patients with allograft rejection and C4d deposition in renal biopsies.
    Alvarez-Márquez A; Aguilera I; Gentil MA; Caro JL; Bernal G; Fernández Alonso J; Acevedo MJ; Cabello V; Wichmann I; Gonzalez-Escribano MF; Núñez-Roldán A
    Transplantation; 2009 Jan; 87(1):94-9. PubMed ID: 19136897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preformed complement-activating low-level donor-specific antibody predicts early antibody-mediated rejection in renal allografts.
    Lawrence C; Willicombe M; Brookes PA; Santos-Nunez E; Bajaj R; Cook T; Roufosse C; Taube D; Warrens AN
    Transplantation; 2013 Jan; 95(2):341-6. PubMed ID: 23197178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid reduction in donor-specific anti-human leukocyte antigen antibodies and reversal of antibody-mediated rejection with bortezomib in pediatric heart transplant patients.
    Morrow WR; Frazier EA; Mahle WT; Harville TO; Pye SE; Knecht KR; Howard EL; Smith RN; Saylors RL; Garcia X; Jaquiss RD; Woodle ES
    Transplantation; 2012 Feb; 93(3):319-24. PubMed ID: 22179403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of complement component 4d immunohistochemistry to ABO-compatible and ABO-incompatible liver transplantation.
    Salah A; Fujimoto M; Yoshizawa A; Yurugi K; Miyagawa-Hayashino A; Sumiyoshi S; Minamiguchi S; Uemoto S; Maekawa T; Haga H
    Liver Transpl; 2014 Feb; 20(2):200-9. PubMed ID: 24470446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Effect of Bortezomib on Antibody-Mediated Rejection after Kidney Transplantation.
    Lee J; Kim BS; Park Y; Lee JG; Lim BJ; Jeong HJ; Kim YS; Huh KH
    Yonsei Med J; 2015 Nov; 56(6):1638-42. PubMed ID: 26446648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Durable renal response after combination of bortezomib, corticosteroids, rituximab, and plasmapheresis for late antibody-mediated renal transplant rejection
.
    Ding Y; Francis J; Gautam A; Pelletier L; Sanchorawala V; Quillen K
    Clin Nephrol; 2018 Apr; 89(4):252-259. PubMed ID: 29208204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. C4D deposition and positive posttransplant crossmatch are not necessarily markers of antibody-mediated rejection in renal allograft recipients.
    Banasik M; Boratyńska M; Nowakowska B; Haloń A; Kościelska-Kasprzak K; Drulis-Fajdasz D; Patrzałek D; Weyde W; Klinger M
    Transplant Proc; 2007 Nov; 39(9):2718-20. PubMed ID: 18021967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bortezomib in late antibody-mediated kidney transplant rejection (BORTEJECT Study): study protocol for a randomized controlled trial.
    Eskandary F; Bond G; Schwaiger E; Kikic Z; Winzer C; Wahrmann M; Marinova L; Haslacher H; Regele H; Oberbauer R; Böhmig GA
    Trials; 2014 Apr; 15():107. PubMed ID: 24708575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Banff Component Scoring-based Histologic Assessment of Bortezomib-based Antibody-mediated Rejection Therapy.
    Sadaka B; Ejaz NS; Shields AR; Cardi MA; Wadih G; Witte D; Abu Jawdeh BG; Alloway RR; Woodle ES
    Transplantation; 2015 Aug; 99(8):1691-9. PubMed ID: 25803498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bortezomib for the treatment of chronic antibody-mediated kidney allograft rejection: a case report.
    Schwaiger E; Regele H; Wahrmann M; Werzowa J; Haidbauer B; Schmidt A; Böhmig GA
    Clin Transpl; 2010; ():391-6. PubMed ID: 21696056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection.
    Eskandary F; Regele H; Baumann L; Bond G; Kozakowski N; Wahrmann M; Hidalgo LG; Haslacher H; Kaltenecker CC; Aretin MB; Oberbauer R; Posch M; Staudenherz A; Handisurya A; Reeve J; Halloran PF; Böhmig GA
    J Am Soc Nephrol; 2018 Feb; 29(2):591-605. PubMed ID: 29242250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma C4d+ Endothelial Microvesicles Increase in Acute Antibody-Mediated Rejection.
    Tower CM; Reyes M; Nelson K; Leca N; Kieran N; Muczynski K; Jefferson JA; Blosser C; Kukla A; Maurer D; Chandler W; Najafian B
    Transplantation; 2017 Sep; 101(9):2235-2243. PubMed ID: 27846156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody-mediated rejection in pediatric liver transplant recipients.
    Markiewicz-Kijewska M; Kaliciński P; Kluge P; Piątosa B; Rękawek A; Jankowska I; Kostecka E; Kurowski PN
    Ann Transplant; 2014 Mar; 19():119-23. PubMed ID: 24594760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The influence of bortezomib on donor specific antibody reduction in patients with antibody mediated rejection.
    Hardinger KL; Murillo D
    Clin Transpl; 2011; ():401-8. PubMed ID: 22755438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.